Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Prevnar Allocation Plan Could Run Through March

Executive Summary

Wyeth expects an allocation program for Prevnar could be in place through March

You may also be interested in...



Wyeth Prevnar Allocation Plan Extended To July; Four-Dose Schedule On Hold

Wyeth's Prevnar allocation program will run until at least mid-July, with shipments to providers cut by 20%

Wyeth Prevnar Allocation Plan Extended To July; Four-Dose Schedule On Hold

Wyeth's Prevnar allocation program will run until at least mid-July, with shipments to providers cut by 20%

Premarin Family Sales Stabilize, Wyeth Says; Price Increases Help

Premarin family sales have leveled off since the sharp decline seen in the months following the release of the Women's Health Initiative study, Wyeth reports

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel